Improved Accuracy of Detection of Nasopharyngeal Carcinoma by Combined Application of Circulating Epstein–Barr Virus DNA and Anti-Epstein–Barr Viral Capsid Antigen IgA Antibody

Leung, Sing Fai; Tam, John S.; Chan, Anthony T.C.; Zee, Benny; Chan, Lisa; Huang, Dolly P.; Hasselt, Andrew van; Johnson, Philip J.; Lo, Y.M. Dennis

doi:10.1373/clinchem.2003.022426

Cited by 101 publications

(90 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Leung et al reported 99% sensitivity and 96% to 98% specificity of this method under diagnostic settings. 43 But despite promising findings, Yang et al cautioned that the close association between plasma EBV DNA and the tumor might render it undetectable when identifying precursor lesions or early stages of NPC. 44 On the basis of independent studies quantifying plasma EBV DNA of primary NPC cases, 45 we found that some EBV microRNAs are present at comparable, if not higher copies and may be more readily detectable than EBV DNA under screening circumstances.…”

Section: Discussionmentioning

confidence: 99%

Profiling of Epstein‐Barr virus‐encoded microRNAs in nasopharyngeal carcinoma reveals potential biomarkers and oncomirs

Wong

Kong

Tsang

et al. 2011

Cancer

143

133

View full text Add to dashboard Cite

BACKGROUND: Epstein-Barr virus (EBV) microRNAs are abundant in nasopharyngeal carcinoma (NPC) tumors. With recent advances in serum microRNA detection, the distinct presence of EBV microRNAs in serum could aid in screening endemic regions for NPC. A proposed network of genes targeted by these microRNAs could also shed light on EBV-associated tumorigenesis. METHODS: MicroRNA microarray profiling of 5 paired NPC biopsies was followed by validation of 12 up-regulated EBV microRNAs (BART1-3p, 2-5p, 5, 6-5p, 6-3p, 7, 8, 9, 14, 17-5p, 18-5p, 19-3p) in 15 additional cases by real-time polymerase chain reaction. Tumor (cellular) and serum microRNA copy numbers from the same 15 patients were correlated. Expression of the same microRNAs were also examined in EBV-positive cell lines C666 and NP460hTERTþEBV. Bioinformatic tools helped predict cellular target genes, which were later confirmed by gene expression analysis. RESULTS: The authors' high-throughput approach shows that EBV microRNAs are generally more up-regulated than microRNAs of human origin. Twenty-nine of 39 EBV microRNAs were significantly up-regulated in tumor versus their nontumor biopsies (P < .05). Upon successfully validating 12 selected EBV microRNAs in 15 additional paired NPC cases, the authors found that their distinct presence in the serum of NPC patients positively correlated with cellular copy numbers of EBV microRNAs. Further investigation of potential EBV microRNA target genes revealed inhibition of tumor suppressor genes (eg, PTEN) and extensive deregulation of several pathways frequently involved in NPC (eg, Wnt signaling). CONCLUSIONS: Increasing knowledge of host-virus interaction via microRNAs may provide feasible explanations underlying NPC tumorigenesis along with the development of biomarkers for screening high-risk populations. Cancer 2012;118:698-

show abstract

Section: Discussionmentioning

confidence: 99%

Profiling of Epstein‐Barr virus‐encoded microRNAs in nasopharyngeal carcinoma reveals potential biomarkers and oncomirs

Wong

Kong

Tsang

et al. 2011

Cancer

143

133

View full text Add to dashboard Cite

show abstract

“…Patients with more rapid clearance of EBV DNA from the circulation responded better to treatment and had a better survival probability [22,23]. Due to high sensitivity and specificity [24,25], plasma EBV DNA has been adopted as a marker for clinical management of patients with NPC [26]. It was suggested that high circulating plasma EBV DNA load assessed 6 weeks post-primary treatment may predict a subsequent relapse [27][28][29].…”

Section: Discussionmentioning

confidence: 99%

Post-Treatment Circulating Free HPV DNA As a Marker of Treatment Outcome in Patients with HPV-Related Propharyngeal Cancer After Radio(chemo)therapy

Tw¹,

Mazurek²,

Ånietura³

et al. 2017

Cell Mol Med

View full text Add to dashboard Cite

Circulating cell-free HPV16 DNA (cfHPV DNA) assessed after treatment completion was tested as a prognostic marker of treatment failure in patients with HPVrelated oropharyngeal cancer (OPC) treated with radiotherapy alone (RT) or radiotherapy combined with chemotherapy (CHRT). Fifty-five patients with OPC in whom cfHPV DNA was found prior to RT/CHRT were included into the study. cfHPV DNA was subsequently assessed after treatment completion. cfHPV DNA remission (cfHPVrem) was defined as the absence of cfHPV DNA after treatment completion. The association between cfHPVrem and the risk of local, nodal or distant failure was calculated. Survival curves were calculated according to the Kaplan-Meier technique and compared according to cfHPVrem after treatment completion with the log-rank test. Thirteen (24%) patients presented no cfHPVrem after treatment completion. For these patients, the risk of nodal failure was significantly higher (HR=9.38, 95% CI: 1.63-53.97, p=0.009) than for patients with cfHPVrem. The probability of dissemination was comparable in patients with cfHPVrem and with no cfHPVrem (p=0.95). For patients with HPV related OPC, who has no cfHPVrem after RT/CHRT completion stricter follow up is proposed due to higher risk of nodal failure.

show abstract

“…Fluctuations of serological antibodies can be observed and can lead to false results (13). Improved accuracy by combining application of circulating viral DNA and antibody is recommended (14). Focusing on the cost effectiveness issue, it is accepted that the screening can be useful only for the high risk population in non-endemic country (15).…”

Section: Ebv Serological Tool For Early Prevention Of Nasopharyngeal mentioning

confidence: 99%

Serological Screening Test as a Tool for Early Prevention of Cancerous Disorders

Wiwanitkit¹

2012

Jundishapur J Microbiol

View full text Add to dashboard Cite

In medicine, there are many new evidence that some infections are the underlying risks contributing to the pre-cancerous lesion. The best examples are hepatitis infection that can lead to hepatoma and Helicobacter pylori infection which cause gastric carcinoma. The infectious induced cancers are important groups of cancers that are presently focused as preventable cancers. Since the infection is the early phase before development of pre-cancerous lesion, hence determination and treatment of infection means very early cutoff of the carcinogenesis process. The concept of cancer early diagnosis at present tends to the serological screening for the precancerous problem that is useful as a preventive mean for cancer control. The microbiological serological test becomes an important tool for this purpose. Several serodiagnostic tests are available as tools for early diagnosis of pre-cancerous lesions. In this specific brief article, the author summarizes and presents on some important serological screening that can be used as tools for early diagnosis and prevention of cancers. The main aim of this paper is to introduce the usage of screening test focusing on its effectiveness, pitfall and critical concerns, not on the already well-known pathology of infection induced carcinogenesis process.

show abstract

Improved Accuracy of Detection of Nasopharyngeal Carcinoma by Combined Application of Circulating Epstein–Barr Virus DNA and Anti-Epstein–Barr Viral Capsid Antigen IgA Antibody

Cited by 101 publications

References 41 publications

Profiling of Epstein‐Barr virus‐encoded microRNAs in nasopharyngeal carcinoma reveals potential biomarkers and oncomirs

Profiling of Epstein‐Barr virus‐encoded microRNAs in nasopharyngeal carcinoma reveals potential biomarkers and oncomirs

Post-Treatment Circulating Free HPV DNA As a Marker of Treatment Outcome in Patients with HPV-Related Propharyngeal Cancer After Radio(chemo)therapy

Serological Screening Test as a Tool for Early Prevention of Cancerous Disorders

Contact Info

Product

Resources

About